PNC-27 vs PQQ
A side-by-side research comparison of PNC-27 and PQQ across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PNC-27 | PQQ |
|---|---|---|
| Full name | PNC-27 (p53-Derived Anticancer Peptide) | Pyrroloquinoline Quinone (BioPQQ) |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | Research compound (preclinical) | Dietary supplement (GRAS) |
| Mechanism | Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies. | Activates PGC-1α (master mitochondrial biogenesis regulator) via CREB phosphorylation. Catalytic antioxidant that undergoes 20,000+ redox cycles vs one-time use of vitamin C. Stimulates NGF synthesis for neuroprotection. |
| Molecular weight | ~3.2 kDa | 330.21 Da |
| Half-life | Short (peptide) | ~3-5 hours |
| Bioavailability | Injection (research) | ~60% oral |
| Typical dose | Not established for humans | 10-20 mg |
| Frequency | Research only | Daily |
| Route | Injection (research) | Oral capsule |
PNC-27 reported benefits
- Selective cancer-cell targeting (preclinical)
- p53/HDM-2 mechanism of interest
- Reported sparing of normal cells (studies)
PQQ reported benefits
- Mitochondrial biogenesis (new mitochondria)
- Potent antioxidant (catalytic)
- Nerve growth factor stimulation
- Improved sleep quality
- Enhanced cognitive function
- Cellular energy optimization
Related comparisons
Research and educational reference only. Not medical advice.